VivoSeq
Other

Skin Rash

8

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Skin rash is an early-stage landscape with 8 programs across 5 companies. The most active players are TWi Biotechnology, Inc., Glaxo Dba Glaxosmithkline, Pfizer. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TWi Biotechnology, Inc.

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2GSK logo

GSK

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Unknown status2 · 29%
Withdrawn1 · 14%

Clinical Trials

Trial Activity

7 trials

Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer
Completed·Alliance for Clinical Trials in Oncology·N/A·NCT00091247·130 enrolled
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
Completed·UUniversity of Louisville·Phase 2·NCT01874860·24 enrolled
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
Completed·TTWi Biotechnology, Inc.·Phase 2·NCT04239846·74 enrolled
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Completed·Alliance for Clinical Trials in Oncology·Phase 3·NCT00362986·116 enrolled
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
Withdrawn·UUniversity of Pittsburgh·Phase 4·NCT01299220
Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients
Unknown status·SSeoul National University Hospital·Phase 2·NCT03220256·30 enrolled
A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash
Unknown status·SShanghai East Hospital·N/A·NCT05120362·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)